Evoke Pharma Receivables 2012-2024 | EVOK

Evoke Pharma receivables from 2012 to 2024. Receivables can be defined as the total amount of collectibles for a company
Evoke Pharma Annual Receivables
(Millions of US $)
2023 $1
2022 $1
2021 $0
2020 $0
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
Evoke Pharma Quarterly Receivables
(Millions of US $)
2024-06-30 $2
2024-03-31 $1
2023-12-31 $1
2023-09-30 $1
2023-06-30 $1
2023-03-31 $1
2022-12-31 $1
2022-09-30 $1
2022-06-30 $0
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.004B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Teligent (TLGT) United States $0.000B 0.00